NLM Digital Collections

Search

Start Over Subjects United States ✖Remove constraint Subjects: United States Publication Year 2000 to 2024 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2000">2000</span> to <span class="to" data-blrl-end="2024">2024</span>

61. Opioids in Ohio Medicaid: review of extreme use and prescribing

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, July 2018
Subject(s):
Analgesics, Opioid -- therapeutic use
Inappropriate Prescribing
Medicaid
Opioid-Related Disorders -- epidemiology
Opioid-Related Disorders -- prevention & control
Prescription Drug Misuse
Analgesics, Opioid -- administration & dosage
Humans
Ohio
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

64. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

65. Questionable billing for compounded topical drugs in Medicare Part D

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018
Subject(s):
Dermatologic Agents -- economics
Dermatologic Agents -- therapeutic use
Drug Compounding -- economics
Drug Utilization -- trends
Fraud
Insurance, Health, Reimbursement
Medicare Part D -- economics
Skin Cream -- economics
Administration, Topical
Dermatologic Agents -- adverse effects
Drug Compounding -- standards
Forecasting
Health Expenditures -- trends
Insurance Coverage
Skin Cream -- adverse effects
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

66. FDA should further integrate its review of cybersecurity into the premarket review process for medical devices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2018
Subject(s):
Computer Security
Device Approval -- standards
Equipment and Supplies -- standards
Equipment Safety -- standards
Computer Communication Networks -- standards
Guidelines as Topic
Software -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

67. Treatment planning and medication monitoring were lacking for children in foster care receiving psychotropic medication

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2018
Subject(s):
Antipsychotic Agents -- therapeutic use
Foster Home Care
Medication Therapy Management
Patient Care Planning
Child
Child Health Services -- standards
Inappropriate Prescribing
Mental Disorders -- drug therapy
Practice Guidelines as Topic
State Government
Humans
United States
United States. Department of Health and Human Services.

68. Medicare payments for clinical diagnostic laboratory tests in 2017: year 4 of baseline data

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2018
Subject(s):
Clinical Laboratory Techniques -- economics
Insurance, Health, Reimbursement
Medicare Part B -- economics
Prospective Payment System
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)